Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab with Chemoradiation for Locally Advanced Pancreatic Cancer
NCT01175733Phase 2Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Jul 2010
- Primary completion
- Mar 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panitumumab in pancreatic cancer (PC), sponsored by Amsterdam University Medical Center. Primary endpoints: Recommended Safe Dosing at 43 days, Progression-Free Survival Rate at 7 months and 1 more. Started Jul 2010; status: completed.
02
Drugs
panitumumab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT01175733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01175733.